US Patent Issued to AbelZeta on March 24 for "Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof" (Chinese, American Inventors)

ALEXANDRIA, Va., March 24 -- United States Patent no. 12,583,903, issued on March 24, was assigned to AbelZeta Inc. (Rockville, Md.).

"Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof" was invented by Yihong Yao (Rockville, Md.), Jiaqi Huang (Rockville, Md.), Shigui Zhu (Rockville, Md.), Wei Zhu (Rockville, Md.), Xin Yao (Rockville, Md.), Zhiyuan Li (Hong Kong), Li Zhang (Rockville, Md.), Lin Zhu (Hong Kong), Anyun Ma (Hong Kong), Yutian Wei (Hong Kong), Yanfeng Li (Hong Kong), Qingxia Wang (Hong Kong) and Jiaping He (Hong Kong).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are a chimeric antigen receptor targeting CD20 antige...